EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies

John Glaspy iD, Nashat Y Gabrail, Patricia Locantore-Ford, Tyson Lee, Katharina Modelska, Vivek Samal, David H Henry iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26865 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2023. Verfasst von John Glaspy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Anemia, Antineoplastic Agents, Neoplasms, Hematinics. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FibroGen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy‐induced anemia (CIA) management options are suboptimal. We evaluated the efficacy and safety of roxadustat in this setting. This open‐label Phase 2 study included patients with non‐myeloid malignancies and CIA (hemoglobin [Hb] ≤10 g/dL) who had planned concurrent myelosuppressive chemotherapy for ≥8 additional weeks. Oral roxadustat was administered for ≤16 weeks (starting dose 2.0 or 2.5 mg/kg, then titrated every 4 weeks). The primary efficacy endpoint was mean maximum change in Hb within 16 weeks of baseline without red blood cell (RBC) transfusion. Patients were assigned to roxadustat 2.0 ( n = 31) or 2.5 mg/kg ( n = 61) starting doses, and 89 were assessed for efficacy. The mean (standard deviation) maximum Hb change from baseline without RBC transfusion was 2.4 (1.5) and 2.5 (1.5) g/dL in the roxadustat 2.0 and 2.5 mg/kg groups, respectively. Median (range) time to Hb increase of ≥2 g/dL was 71 (57–92) days. Twelve patients (14.5%) had RBC transfusions (Week 5 to the end of treatment). Roxadustat was efficacious regardless of tumor type and chemotherapy regimen. Deep vein thrombosis (DVT) and pulmonary embolism (PE) occurred in 14 (15.2%) and nine (9.8%) patients, respectively, and three had serious adverse events attributed to roxadustat in the opinion of the investigators (PE: n = 2 [2.2%]; DVT: n = 1 [1.1%]). Roxadustat increased Hb in patients with CIA regardless of tumor type and chemotherapy regimen. Adverse events were consistent with observations in patients with advanced‐stage malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaAntineoplastic AgentsNeoplasmsHematinicsErythropoietinHumansHemoglobinsGlycineIsoquinolines

Substanzen

HemoglobinsAntineoplastic AgentsGlycineIsoquinolinesHematinicsErythropoietin

Autor:innen und Institutionen

  • Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California, USA.
  • Department of Oncology, Gabrail Cancer Center, Canton, Ohio, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Clinical Development, FibroGen, Inc., San Francisco, California, USA.
  • Department of Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania, USA.

ORCID-Profile: John Glaspy, David H Henry

Förderung

  • FibroGen

Zitieren

APA

Glaspy, J., Gabrail, N. Y., Locantore-Ford, P., Lee, T., Modelska, K., Samal, V., & Henry, D. H. (2023). Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies. American Journal of Hematology. https://doi.org/10.1002/ajh.26865

Vancouver

Glaspy J, Gabrail NY, Locantore-Ford P, Lee T, Modelska K, Samal V, et al. Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies. American Journal of Hematology. 2023. doi:10.1002/ajh.26865

BibTeX
@article{Glaspy2023,
  author = {Glaspy, John and Gabrail, Nashat Y and Locantore-Ford, Patricia and Lee, Tyson and Modelska, Katharina and Samal, Vivek and Henry, David H},
  title = {Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26865}
}
Kostenlos starten →